Prognosis of men whose first manifestation of coronary heart disease was angina without antecedent infarction was found to resemble closely that of inen followed after an initial MI. Overall mortality over a period of 4.5 years following a baseline examination was the same in the two cohorts: 17.5%.
on the prognosis of angina among men, covering a period of 30 months following a baseline examination, have been published.' The current report will deal with prognosis of men during the first 5 years after clinical onset of angina, with emphasis on the prognostic significance of selected medical parameters.
Methods
The general population at risk for the development of angina consisted of some 110,000 men and women aged 25-64, enrolled for at least 2 years in the Health Insurance Plan of Greater New York (HIP), a prepaid comprehensive group practice plan. Patients within this population who sought medical care for symptoms suggestive of coronary disease during the 4 case-finding years, [1961] [1962] [1963] [1964] [1965] , were invited to the study's baseline examination, and 90% responded. The primary source for identification of such patients was systematic scanning of all service reports routinely received from HIP family physicians and internists for a wide range of cardiovascular terminology. 5 The diagnosis of angina was based entirely upon an assessment of a structured medical history recorded by the study's internist at the baseline examination. Criteria, summarized in appendix A, were developed to permit a consistent weighting of the various features of the pain syndrome.2 Descriptions meeting these criteria would usually be considered as convincing histories of definite angina pectoris. Ex- cluded from the angina cohort were patients with aortic valvular disease and those who had suffered a definite myocardial infarction before the baseline examination.
The diagnosis was further restricted to patients who had the syndrome for a minimum of 2 months, in order to provide sufficient time for the characteristics to be well defined and to avoid the inclusion of patients with acute preinfarction angina.
Men first meeting the study's criteria for definite angina in the 4 years of case finding (1961) (1962) (1963) (1964) (1965) constitute the cohort whose prognosis is to be presented. During the same time period a myocardial infarction (MI) cohort was also developed-men under age 65 who suffered an initial MI as evidenced by defined highly specific electrocardiographic abnormalities or, alternatively, with characteristic ECG abnormalities associated with a combination of appropriate clinical symptoms and acute phase reactants.2 Survivors of such first attacks were invited to the study's baseline examination, and their prognosis is used as a frame of reference in presenting the current data.
For men in both the angina and infarction cohorts the baseline examination was conducted, on the average, about 6 months after diagnosis. All patients entering a prognostic cohort were scheduled for study The 4.5-year follow-up data here presented confirm previously reported findings from the HIP study showing no apparent disadvantage associated with elevated serum cholesterol levels among men with either first MI or angina without antecedent MI. 9 The Canadian studies by Shanoff et al. of male MI survivors followed over a 10-year period have similarly found no relationship between survival and serum lipid level.10 Several clinical trials of lipid-lowering drugs have reported the experience of men treated only with placebos in relation to their initial serum cholesterol level. In the Scottish clofibrate trial" almost identical rates of "events" over a 6-year period were experienced by men with a high serum cholesterol (over 260 mg/ml) and those with lower values (260 or less) both among the men who had had a first MI and those who had presented with angina. In the similar clofibrate trial in Newcastle-upon-Tyne, however, the placebotreated men with initial cholesterol exceeding 260 mg/ml showed somewhat higher rates of "events" over the 5-year observation period than the comparable men with initial cholesterol levels of 260 or less.'2 In both these studies it was pointed out by the authors that the protective action of the clofibrate against new infarets and death bore no apparent relation to the cholesterol-and triglyceride-reducing properties of the drug. But recently presented data for placebo-treated men from the Coronary Drug Project show a somewhat lower mortality over an average follow-up period of 3 years among men with initial cholesterol less than 250 mg/ml (11.5%) than among those with higher levels (14.7%). '3 It is plausible to suggest that the level of serum cholesterol in a general population reflects the amount of arterial fatty streaking and atheroma formation which leads ultimately to fibrous plaque formation. The continued growth of these plaques-with formation of excess fibromuscular scar, calcification, cracking of the intima, extrusion of contents, subintimal hemorrhage, platelet aggregation, and intraluminal thrombosis-may lead to progressive coronary artery occlusion without relation to the general or local lipid metabolism or serum cholesterol level. Hyperlipidemia undoubtedly favors the initiating steps leading to vascular atheromatosis and fibrous plaques, but other factors may become more relevant to the subsequent progression of these lesions.
Hypertension may represent one type of vascular stress that accelerates degenerative processes in the arteriosclerotic plaques of men with coronary disease. Hypertension also represents an increased "afterload" to the left ventricle and leads to myocardial hypertrophy. Both these circumstances contribute to an increased requirement for coronary blood flow. The necessity for increased coronary flow, coupled with accelerated disease of the coronary arteries, may explain in part the relatively poor prognosis of hypertensive men with CHD, noted here and previously from the HIP study.1 14-16 It must be emphasized that the findings here reported on prognosis with respect to serum cholesterol and elevated blood pressure are for men surviving a first MI or diagnosis of angina. The prognosis of women with such newly diagnosed coronary heart disease in relation to blood pressure and cholesterol levels is quite different. 3' 9 Neither is it possible to draw any conclusions from these observations about any potential benefits which might result from the treatment of elevated blood pressure in men with coronary disease.
Electrocardiographic findings at the baseline examination were of great prognostic significance. Both in the angina and MI cohorts the men with specified ECG abnormalities showed three times the risk of cardiac death found among the other men over the 4.5 years of observation. It is likely that the presence of an abnormal ECG in a coronary population identifies patients with relatively more extensive pathology. Horizontal depressions of the S-T segment may imply persisting ischemia, presumably from more extensive obstruction to coronary blood flow. Other abnormalities, such as T-wave inversions, may reflect myocardial damage not specific enough for a diagnosis of infarction but sufficiently important to influence prognosis. In this connection it is of interest that a recent analysis of the men in the placebo group of the Coronary Drug Project'7 noted among these 2789 MI survivors followed for an average period of 30 months that of 100 baseline variables the one showing the largest independent association with total mortality was S-T-segment depression. In the HIP experience here presented (table 2) mortality risk among men with abnormal ECGs was more than twice that of the other men in the angina cohort and more than three times that of men without abnormal ECGs in the MI cohort. The HIP angina cohort excluded patients with a history of or with definite ECG evidence of myocardial infarction. The S-T and T-wave abnormalities in this population were nevertheless associated with a Circulation, Volume XLVII, March 1973 distinctly adverse prognosis whether or not hypertension was present. The combination of elevated blood pressure and an abnormal ECG was associated with a particularly poor prognosis.
These findings may be relevant to current concerns about selection of patients for surgical therapy of coronary heart disease. Table 7 presents a prognostic classification of the total 745 male coronary patients based upon the ECG and blood pressure findings. Almost one fourth (23%) of the men had both an abnormal ECG and an elevated blood pressure; the probability of cardiac death over the 4.5 years of observation for these men was 32 of 100. In contrast, slightly over one fourth (26%) of the men with coronary heart disease of recent origin were free of hypertension and did not show an abnormal ECG at baseline. For them the 4.5-year probability of cardiac death was only six of 100. Thus half of this study population-readily identified by simple, noninvasive technics-could be classified into groups with very different prognosis. Since the total 4.5-year mortality of the "low-risk" group approximates that to be expected as an immediate operative mortality during coronary bypass surgery, and since any reduction in mortality risk associated with successful surgery of this type has yet to be demonstrated, it is not reasonable to attempt to prove surgical benefit in patients of this type. It is of importance also that the overall mortality experience of the "low-risk" men in the coronary cohorts (ECG not abnormal and blood pressure not elevated) is only moderately higher than that of an age-comparable random sample of men from the same general population who were initially free of recognized heart disease at the start of the 4.5-year observation period (eight of 100 compared with five of 100).
In contrast, the fourth of the patients defined as at "high risk"-with an estimated probability of cardiac death in 32 of 100 over the 4.5 tFleeting pain, characterized as lasting only for seconds, produces no score.
tOnly the single highest negative score from these items is tallied. §If "no relief by rest" seems clearly related to the fact that the patient always takes NTG, no negative score is applied here. 
